![Page Image](https://mumcdnstorage.blob.core.windows.net/dwnews/2023/09/Neph_Times_Square_Logo_500x500.png)
ASN Kidney Week 2024: Focus on Gout
Abdul Abdellatif discussed findings from the PROTECT study examining pegloticase for kidney transplant patients with gout.
Aquapheresis may provide an alternative for fluid removal in hypervolemia patients with sickle cell nephropathy.
Researchers reported on a patient with elevated 1,25-dihydroxyvitamin D with hypercalcemia and severe tophaceous gout.
A case report suggests treatment with intravenous pegloticase could help eGFR recovery in patients with uncontrolled gout.
A study examined gout incidence and risk among stage 3-5 CKD patients with asymptomatic hyperuricemia.
A study examined the prevalence, patient characteristics, and medical management of patients with gout and CKD.
A patient with gout experienced an increased risk of kidney stone formation after adopting a carnivore diet.
Researchers presented bone-related findings of a study on pegloticase use in kidney transplant recipients with gout.
Researchers explored an association between fluctuating uric acid levels and adverse prognoses in older adults with CKD.
A study examined the association between the prescription of ULT and the progression of kidney disease in patients with CKD.
Advertisement
Advertisement